• Craft brewer Malt Fiction has released its latest ale in a can format.
    Craft brewer Malt Fiction has released its latest ale in a can format.
Close×

A team of craft beer enthusiasts in Adelaide have released their latest brew in a can instead of the traditional bottle.

The brand, Malt Fiction, was launched with the introduction of a bottled pale ale named '13' in 2014.

Following success of its inaugural brew, Malt Fiction's latest release is Session Ale, which is packaged in a new can format.

Head-brewer Jared Birbeck said he and his team made a “conscious decision” to sell Session Ale in a trendy 375ml can rather than a glass bottle.

“Cans are 100 per cent recyclable, allowing us to increase the quality and quantity of our brews,” Birbeck says.

“Cans also preserve the beer’s flavour and shelf life due to limited light and oxygen exposure.”

The cans are supplied by Orora Beverages and the filling is done by Icon Brewery, which is based in Sydney.

The ale has the addition of an extra hop and a more prominent crisp finish with slightly bitter yet fruity characteristics.

“Preserving true craftsmanship, Session Ale has been brewed with natural ingredients and traditional techniques, containing no added artificial ingredients, flavours or preservatives,” he says.

“It contains 1.3 standard drinks with an abv/vol of 4.5%.”

Malt Fiction brews its beers at several local South Australian breweries.

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.